Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This research aims to incorporate ctDNA analysis into clinical practice to individualize
therapy in patients with stage III NSCLC by moving to a treatment-by-marker based approach
(as opposed to treatment based on clinical or radiographic evidence of disease).